Direxion Daily S&P Biotech Bull 3x Shares Rating $273.95 +0.04 (+0.01%) As of 02:47 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Direxion Daily S&P Biotech Bull 3x Shares Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.LABU Aggregate RatingModerate Buy 2.74Holdings in LABU have an aggregate rating of Moderate Buy based on 270 analyst ratings issued in the past year covering 16 companies (14.4% of the portfolio).LABU Aggregate Price Target$271.02-0.57% DownsideHigh Prediction$271.02Average Prediction$271.02Low Prediction$271.02Holdings in LABU have an aggregate price target of $271.02 and a range of $271.02 to $271.02 covering 16 companies (14.4% of the portfolio).LABU Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Direxion Daily S&P Biotech Bull 3x Shares Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 16 LABU Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.13%APGEApogee Therapeutics$134.56+0.1%1.0034 of 5 stars2.20$124.43 -7.5%20Earnings ReportAnalyst Downgrade0.96%ORKAOruka Therapeutics$109.39+1.2%3.1811 of 5 stars2.82$134.30 22.8%11News CoverageEarnings ReportAnalyst Forecast0.95%DNTHDianthus Therapeutics$114.19+4.2%1.9559 of 5 stars2.93$124.27 8.8%14Insider Trade0.94%KYMRKymera Therapeutics$116.81+2.1%1.0472 of 5 stars2.83$125.65 7.6%230.92%ERASErasca$18.22+2.0%2.5837 of 5 stars2.64$22.09 21.2%11Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap Down0.91%SYRESpyre Therapeutics$103.30+1.4%1.7651 of 5 stars2.87$111.69 8.1%15Analyst Forecast0.88%TWSTTwist Bioscience$119.01-5.0%1.3595 of 5 stars2.70$98.30 -17.4%10Insider Trade0.88%CGONCG Oncology$75.06+0.5%2.4562 of 5 stars2.71$83.18 10.8%140.88%COGTCogent Biosciences$37.65+0.9%2.3958 of 5 stars2.85$49.10 30.4%13Positive NewsEarnings ReportAnalyst Forecast0.87%PTGXProtagonist Therapeutics$154.21+1.8%1.6457 of 5 stars2.94$137.86 -10.6%18Analyst UpgradeInsider Trade0.87%RVMDRevolution Medicines$202.57+0.3%2.4215 of 5 stars2.91$161.79 -20.1%22Analyst Forecast0.86%RYTMRhythm Pharmaceuticals$116.17+0.1%3.0423 of 5 stars2.78$142.44 22.6%180.86%BBIOBridgeBio Pharma$79.75-1.8%3.5414 of 5 stars2.83$100.79 26.4%23Trending NewsEarnings ReportAnalyst Forecast0.85%ARWRArrowhead Pharmaceuticals$86.80+1.4%2.0281 of 5 stars2.62$97.33 12.1%130.84%INCYIncyte$120.12-0.3%3.5373 of 5 stars2.43$120.65 0.4%23Analyst Forecast0.84%PRAXPraxis Precision Medicines$365.75-0.7%3.252 of 5 stars3.00$573.05 56.7%22Analyst Revision This page (NYSEARCA:LABU) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...Decentralized Masters | SponsoredWhy I'm sending this one to my own familyBehind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Direxion Daily S&P Biotech Bull 3x Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Direxion Daily S&P Biotech Bull 3x Shares With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
